Details for New Drug Application (NDA): 040530
✉ Email this page to a colleague
NDA 040530 describes TESTOSTERONE CYPIONATE, which is a drug marketed by Am Regent, Cipla, Eugia Pharma, Hikma, Hikma Farmaceutica, Padagis Us, Rising, Sandoz, Sun Pharm Inds Ltd, Watson Labs, Watson Pharms Inc, Wilshire Pharms Inc, Xiromed, and Azurity, and is included in sixteen NDAs. It is available from seventeen suppliers. There are two patents protecting this drug. Additional details are available on the TESTOSTERONE CYPIONATE profile page.
The generic ingredient in TESTOSTERONE CYPIONATE is estradiol cypionate; testosterone cypionate. There are seventy-five drug master file entries for this compound. Additional details are available on the estradiol cypionate; testosterone cypionate profile page.
The generic ingredient in TESTOSTERONE CYPIONATE is estradiol cypionate; testosterone cypionate. There are seventy-five drug master file entries for this compound. Additional details are available on the estradiol cypionate; testosterone cypionate profile page.
Summary for 040530
| Tradename: | TESTOSTERONE CYPIONATE |
| Applicant: | Padagis Us |
| Ingredient: | testosterone cypionate |
| Patents: | 0 |
Pharmacology for NDA: 040530
| Mechanism of Action | Androgen Receptor Agonists |
Suppliers and Packaging for NDA: 040530
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TESTOSTERONE CYPIONATE | testosterone cypionate | INJECTABLE;INJECTION | 040530 | ANDA | Padagis US LLC | 0574-0820 | 0574-0820-01 | 1 VIAL, GLASS in 1 CARTON (0574-0820-01) / 1 mL in 1 VIAL, GLASS |
| TESTOSTERONE CYPIONATE | testosterone cypionate | INJECTABLE;INJECTION | 040530 | ANDA | Padagis US LLC | 0574-0820 | 0574-0820-10 | 1 VIAL, GLASS in 1 CARTON (0574-0820-10) / 10 mL in 1 VIAL, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 200MG/ML | ||||
| Approval Date: | Jan 31, 2005 | TE: | AO | RLD: | No | ||||
Complete Access Available with Subscription
